Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297982836> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4297982836 endingPage "1518" @default.
- W4297982836 startingPage "1518" @default.
- W4297982836 abstract "Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically." @default.
- W4297982836 created "2022-10-01" @default.
- W4297982836 creator A5006150555 @default.
- W4297982836 creator A5007042386 @default.
- W4297982836 creator A5012738162 @default.
- W4297982836 creator A5013763025 @default.
- W4297982836 creator A5014721309 @default.
- W4297982836 creator A5036148777 @default.
- W4297982836 creator A5057991870 @default.
- W4297982836 creator A5060947872 @default.
- W4297982836 creator A5064240367 @default.
- W4297982836 creator A5083971408 @default.
- W4297982836 creator A5090945727 @default.
- W4297982836 date "2022-09-29" @default.
- W4297982836 modified "2023-09-27" @default.
- W4297982836 title "Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest" @default.
- W4297982836 cites W1867780443 @default.
- W4297982836 cites W1974455447 @default.
- W4297982836 cites W1979325667 @default.
- W4297982836 cites W2163545413 @default.
- W4297982836 cites W2517109673 @default.
- W4297982836 cites W2623521568 @default.
- W4297982836 cites W2694182897 @default.
- W4297982836 cites W2806696712 @default.
- W4297982836 cites W2890730116 @default.
- W4297982836 cites W2939066027 @default.
- W4297982836 cites W3009526876 @default.
- W4297982836 cites W3032533521 @default.
- W4297982836 cites W3044116301 @default.
- W4297982836 cites W3092087394 @default.
- W4297982836 cites W3134454558 @default.
- W4297982836 cites W4212990473 @default.
- W4297982836 cites W85084227 @default.
- W4297982836 doi "https://doi.org/10.3390/life12101518" @default.
- W4297982836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36294953" @default.
- W4297982836 hasPublicationYear "2022" @default.
- W4297982836 type Work @default.
- W4297982836 citedByCount "2" @default.
- W4297982836 countsByYear W42979828362022 @default.
- W4297982836 countsByYear W42979828362023 @default.
- W4297982836 crossrefType "journal-article" @default.
- W4297982836 hasAuthorship W4297982836A5006150555 @default.
- W4297982836 hasAuthorship W4297982836A5007042386 @default.
- W4297982836 hasAuthorship W4297982836A5012738162 @default.
- W4297982836 hasAuthorship W4297982836A5013763025 @default.
- W4297982836 hasAuthorship W4297982836A5014721309 @default.
- W4297982836 hasAuthorship W4297982836A5036148777 @default.
- W4297982836 hasAuthorship W4297982836A5057991870 @default.
- W4297982836 hasAuthorship W4297982836A5060947872 @default.
- W4297982836 hasAuthorship W4297982836A5064240367 @default.
- W4297982836 hasAuthorship W4297982836A5083971408 @default.
- W4297982836 hasAuthorship W4297982836A5090945727 @default.
- W4297982836 hasBestOaLocation W42979828361 @default.
- W4297982836 hasConcept C126322002 @default.
- W4297982836 hasConcept C16005928 @default.
- W4297982836 hasConcept C197934379 @default.
- W4297982836 hasConcept C2776002364 @default.
- W4297982836 hasConcept C2779134260 @default.
- W4297982836 hasConcept C2780132546 @default.
- W4297982836 hasConcept C59491497 @default.
- W4297982836 hasConcept C71924100 @default.
- W4297982836 hasConceptScore W4297982836C126322002 @default.
- W4297982836 hasConceptScore W4297982836C16005928 @default.
- W4297982836 hasConceptScore W4297982836C197934379 @default.
- W4297982836 hasConceptScore W4297982836C2776002364 @default.
- W4297982836 hasConceptScore W4297982836C2779134260 @default.
- W4297982836 hasConceptScore W4297982836C2780132546 @default.
- W4297982836 hasConceptScore W4297982836C59491497 @default.
- W4297982836 hasConceptScore W4297982836C71924100 @default.
- W4297982836 hasIssue "10" @default.
- W4297982836 hasLocation W42979828361 @default.
- W4297982836 hasLocation W42979828362 @default.
- W4297982836 hasLocation W42979828363 @default.
- W4297982836 hasOpenAccess W4297982836 @default.
- W4297982836 hasPrimaryLocation W42979828361 @default.
- W4297982836 hasRelatedWork W2800869485 @default.
- W4297982836 hasRelatedWork W2895616269 @default.
- W4297982836 hasRelatedWork W2912355509 @default.
- W4297982836 hasRelatedWork W2973780469 @default.
- W4297982836 hasRelatedWork W3049056607 @default.
- W4297982836 hasRelatedWork W3092087394 @default.
- W4297982836 hasRelatedWork W4212990473 @default.
- W4297982836 hasRelatedWork W4294597836 @default.
- W4297982836 hasRelatedWork W4310642338 @default.
- W4297982836 hasRelatedWork W4386726358 @default.
- W4297982836 hasVolume "12" @default.
- W4297982836 isParatext "false" @default.
- W4297982836 isRetracted "false" @default.
- W4297982836 workType "article" @default.